Molekulare Pathologie benigner gynäkologischer Erkrankungen – ist sie hilfreich bei zukünftigen Therapieentscheidungen?

W. Küpker, Jon Aizpurúa, R. Felberbaum, Jörn Bullerdiek
In: Die Gynäkologie · 2022 · vol. 55(6) , pp. 409–414 · doi:10.1007/s00129-022-04951-4 · W4281481160
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This review discusses the molecular underpinnings of benign gynecological diseases like endometriosis, adenomyosis, and uterine tumors, highlighting how this knowledge may inform future tailored therapies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The article discusses how advances in molecular biology enabling comprehensive gene identification and characterization of genomic and nongenomic actions can reshape understanding of benign gynecologic diseases. It reviews molecular background and altered perspectives for endometriosis, adenomyosis, and uterine tumors, positioning this knowledge as a foundation for new causal and individually tailored therapy options. A key caveat stated by the authors is that they performed no human or animal studies for this contribution, so the piece is not original experimental research. This paper is centrally about endometriosis and adenomyosis only insofar as it uses them as key examples within a broader review of molecular pathology in benign gynecologic diseases.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (34)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK